Inhibition of CD23‐dependent facilitated allergen binding to B cells following vaccination with genetically modified hypoallergenic Bet v 1 molecules |
| |
| Authors: | I Pree M H Shamji I Kimber R Valenta S R Durham V Niederberger |
| |
| Institution: | 1. Department of Otorhinolaryngology, Medical University of Vienna, Vienna, Austria;2. *Contributed equally and are listed in alphabetical order.;3. Section of Allergy and Clinical Immunology, National Heart and Lung Institute, Imperial College, Faculty of Medicine, London, UK;4. Faculty of Life Sciences, University of Manchester, Manchester, UK;5. Christian Doppler Laboratory for Allergy Research, Department of Pathophysiology, Center for Pathophysiology, Infectiology and Immunology, Division of Immunopathology, Medical University of Vienna, Vienna, Austria |
| |
| Abstract: | Background Vaccination with hypoallergenic recombinant Bet v 1 derivatives (Bet v 1 fragments and Bet v 1 trimer) is associated with the induction of IgG antibodies specific to natural Bet v 1. Objective To investigate whether IgG antibodies induced following vaccination with genetically modified hypoallergenic Bet v 1 derivatives are able to inhibit IgE‐facilitated binding of allergen‐IgE complexes to B cells. Methods Sera from 46 patients obtained before and after subcutaneous vaccination with Bet v 1 trimer (n=14), Bet v 1 fragments (n=11) or placebo (n=21) were incubated with recombinant (r) Bet v 1 and an indicator serum (IS) from a birch pollen‐allergic patient with high CD23 binding capacity. Bet v 1 immune complexes were added to a CD23‐expressing B cell line and co‐operative binding of Bet v1‐IgE complexes to CD23 was measured with a polyclonal anti‐IgE FITC antibody using a bio‐functional cellular flow cytometric assay. Results When sera from patients vaccinated with rBet v 1 derivatives were incubated with Bet v 1 and the IS, a reduction of IgE binding to CD23 was observed. This effect was not seen when sera from placebo‐treated patients were used. The decrease in CD23/IgE binding was statistically significant in the trimer group pre‐ vs. post‐specific immunotherapy (SIT): P=0.02; trimer vs. placebo: P<0.04] but not in the Bet v 1 fragments‐treated group. Trimer‐treated patients had higher levels of Bet v 1‐specific IgG than fragment‐treated patients. The degree of inhibitory activity of IgE‐facilitated allergen binding correlated with Bet v 1‐specific IgG levels following SIT (R=0.492; P=0.012). Conclusion Vaccination with both recombinant Bet v 1 derivatives induces Bet v 1‐specific IgG antibodies, which are able to inhibit the co‐operative binding of allergen‐IgE complexes to CD23, and may thereby reduce allergen‐specific T cell responses. Cite this as: I. Pree, M. H. Shamji, I. Kimber, R. Valenta, S. R. Durham and V. Niederberger, Clinical & Experimental Allergy, 2010 (40) 1346–1352. |
| |
| Keywords: | Bet v 1 derivatives CD23 IgE‐facilitated allergen presentation immunotherapy recombinant allergen |
|
|
